Repository logo
 

The Proteasome Distinguishes between Heterotypic and Homotypic Lysine-11-Linked Polyubiquitin Chains.


Type

Article

Change log

Authors

Grice, Guinevere L 
Lobb, Ian T 
Weekes, Michael P 
Gygi, Steven P 
Antrobus, Robin 

Abstract

Proteasome-mediated degradation occurs with proteins principally modified with lysine-48 polyubiquitin chains. Whether the proteasome also can bind atypical ubiquitin chains, including those linked by lysine-11, has not been well established. This is critically important, as lysine-11 polyubiquitination has been implicated in both proteasome-mediated degradation and non-degradative outcomes. Here we demonstrate that pure homotypic lysine-11-linked chains do not bind strongly to the mammalian proteasome. By contrast, heterotypic polyubiquitin chains, containing lysine-11 and lysine-48 linkages, not only bind to the proteasome but also stimulate the proteasomal degradation of the cell-cycle regulator cyclin B1. Thus, while heterotypic lysine-11-linked chains facilitate proteasomal degradation, homotypic lysine-11 linkages adopt conformations that prevent association with the proteasome. Our data demonstrate the capacity of the proteasome to bind ubiquitin chains of distinct topology, with implications for the recognition and diverse biological functions of mixed ubiquitin chains.

Description

Keywords

Amino Acid Sequence, Cyclin B1, HeLa Cells, Humans, Lysine, Molecular Sequence Data, Polyubiquitin, Proteasome Endopeptidase Complex, Protein Binding, Proteolysis, Substrate Specificity, Ubiquitination

Journal Title

Cell Rep

Conference Name

Journal ISSN

2211-1247
2211-1247

Volume Title

12

Publisher

Elsevier BV
Sponsorship
Wellcome Trust (102770/Z/13/Z)
Wellcome Trust (093966/Z/10/Z)
Medical Research Council (G0802822)
Wellcome Trust (100140/Z/12/Z)
Wellcome Trust (108070/Z/15/Z)
This work is supported by a Wellcome Trust Senior Clinical Research Fellowship to JAN (102770/Z/13/Z), a Wellcome Trust Fellowship to MPW (093966/Z/10/Z) and a National Institute of Health grant (GM067945) to SPG. The Cambridge Institutefor Medical Research is in receipt of a Wellcome Trust Strategic Award [100140].